BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Potsch DV, Oliveira ML, Ginuíno C, Miguel JC, Oliveira SA, Silva EF, Moreira RB, Cruz GV, Oliveira AL, Camacho LA. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2010;28:1447-1450. [PMID: 19995540 DOI: 10.1016/j.vaccine.2009.11.066] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Attia KA, Eholié S, Messou E, Danel C, Polneau S, Chenal H, Toni T, Mbamy M, Seyler C, Wakasugi N, N’dri-Yoman T, Anglaret X. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol 2012; 4(7): 218-223 [PMID: 22855697 DOI: 10.4254/wjh.v4.i7.218] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
2 Chaiwarith R, Praparattanapan J, Kotarathititum W, Wipasa J, Chaiklang K, Supparatpinyo K. Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial. AIDS Res Ther 2019;16:33. [PMID: 31711528 DOI: 10.1186/s12981-019-0249-8] [Reference Citation Analysis]
3 Orlando R, Foggia M, Maraolo AE, Mascolo S, Palmiero G, Tambaro O, Tosone G. Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis. 2015;34:1059-1070. [PMID: 25678010 DOI: 10.1007/s10096-015-2341-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
4 Nicolini LA, Magne F, Signori A, Di Biagio A, Sticchi L, Paganino C, Durando P, Viscoli C. Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course. AIDS Res Hum Retroviruses 2018;34:922-8. [PMID: 29926738 DOI: 10.1089/AID.2017.0070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12:966-976. [PMID: 23174382 DOI: 10.1016/s1473-3099(12)70243-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
6 Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: A review. Hum Vaccin Immunother 2017;13:1-10. [PMID: 28267387 DOI: 10.1080/21645515.2016.1277844] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
7 Valats JC, Tuaillon E, Funakoshi N, Hoa D, Brabet MC, Bolloré K, Ducos J, Vendrell JP, Blanc P. Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination. Vaccine 2010;28:6411-6. [PMID: 20682363 DOI: 10.1016/j.vaccine.2010.07.058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
8 Sodhi JS, Raja W, Zargar SA, Showkat A, Parveen S, Nisar S, Wani MA, Javid G, Khan M, Aejaz S, Mohd G, Jan A, Yattoo GN, Shah A, Gulzar GM, Lone R. The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy. Indian J Gastroenterol 2015;34:372-9. [PMID: 26531066 DOI: 10.1007/s12664-015-0595-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Mena G, Llupià A, García-basteiro AL, Díez C, León A, García F, Bayas JM. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012;30:3703-9. [DOI: 10.1016/j.vaccine.2012.03.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
10 Mizusawa M, Perlman DC, Lucido D, Salomon N. Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2014;25:201-6. [PMID: 24216032 DOI: 10.1177/0956462413495820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
11 Dlamini SK, Madhi SA, Muloiwa R, Von Gottberg A, Moosa MS, Meiring ST, Wiysonge CS, Hefer E, Mulaudzi MB, Nuttall J, Moorhouse M, Kagina BM. Guidelines for the vaccination of HIV-infected adolescents and adults in South Africa. South Afr j HIV med 2018;19. [DOI: 10.4102/sajhivmed.v19i1.839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
12 Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine. 2010;28:5597-5604. [PMID: 20600512 DOI: 10.1016/j.vaccine.2010.06.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
13 Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World J Gastroenterol 2014; 20(40): 14598-14614 [PMID: 25356024 DOI: 10.3748/wjg.v20.i40.14598] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
14 Sayad B, Alavian SM, Najafi F, Soltani B, Shirvani M, Janbakhsh A, Mansouri F, Afsharian M, Vaziri S, Alikhani A, Bashiri H. Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in HIV/ AIDS Patients: A Randomized Controlled Trial. Hepat Mon 2012;12:e6234. [PMID: 23087761 DOI: 10.5812/hepatmon.6234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Farooq PD, Sherman KE. Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV. Curr HIV/AIDS Rep 2019;16:395-403. [PMID: 31468298 DOI: 10.1007/s11904-019-00461-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, Dhanireddy S, Baeten JM. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis. 2013;207:402-410. [PMID: 23175769 DOI: 10.1093/infdis/jis695] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
17 Phung BC, Launay O. Vaccination against viral hepatitis of HIV-1 infected patients. Hum Vaccin Immunother 2012;8:554-9. [PMID: 22634451 DOI: 10.4161/hv.19105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
18 Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E, McSorley J, Pozniak A, Rodger A. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. HIV Med 2016;17 Suppl 3:s2-s81. [PMID: 27568789 DOI: 10.1111/hiv.12424] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
19 Mutwa PR, Boer KR, Rusine JB, Muganga N, Tuyishimire D, Reiss P, Lange JM, Geelen SP. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr Infect Dis J 2013;32:246-51. [PMID: 22976050 DOI: 10.1097/INF.0b013e318271b93d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
20 Fuster F, Vargas JI, Jensen D, Sarmiento V, Acuña P, Peirano F, Fuster F, Arab JP, Martínez F; Core-HIV Study Group. CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study. Vaccine 2016;34:1889-95. [PMID: 26945101 DOI: 10.1016/j.vaccine.2016.02.055] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
21 Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, Carrat F; ANRS HB04 B-BOOST study group. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015;15:1283-91. [PMID: 26257021 DOI: 10.1016/S1473-3099(15)00220-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
22 Goncalves PH, Montezuma-Rusca JM, Yarchoan R, Uldrick TS. Cancer prevention in HIV-infected populations. Semin Oncol 2016;43:173-88. [PMID: 26970136 DOI: 10.1053/j.seminoncol.2015.09.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
23 Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS 2013;24:117-22. [DOI: 10.1177/0956462412472309] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
24 Mena G, García-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Hum Vaccin Immunother 2015;11:2582-98. [PMID: 26208678 DOI: 10.1080/21645515.2015.1055424] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
25 Williams H, Bevan MA, Tong CY, Kulasegaram R. Vaccination against hepatitis B in an HIV outpatients' department: an audit against national vaccination guidelines. Int J STD AIDS 2011;22:405-6. [PMID: 21729961 DOI: 10.1258/ijsa.2011.010503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Herrero-Fernández I, Pacheco YM, Genebat M, Rodriguez-Méndez MDM, Lozano MDC, Polaino MJ, Rosado-Sánchez I, Tarancón-Diez L, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M. Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response. Antimicrob Agents Chemother 2018;62:e02050-17. [PMID: 29084751 DOI: 10.1128/AAC.02050-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
27 Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, Silva EF, Mendonça RM, Moreira RB, Barroso PF. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine. 2012;30:5973-5977. [PMID: 22828589 DOI: 10.1016/j.vaccine.2012.07.028] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
28 Martins Rde M, Possas Cde A, Homma A. Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues. Mem Inst Oswaldo Cruz 2015;110:114-24. [PMID: 25742271 DOI: 10.1590/0074-02760140346] [Reference Citation Analysis]